Table I.
Baseline characteristics of the 13 randomized control trials included in the meta-analysis.
| Patients (n) | |||||||
|---|---|---|---|---|---|---|---|
| Author, year | T-group | C-group | T | T-group treatment | C-group treatment | Follow-up (months)a | (Refs.) |
| Adjuvant chemotherapy | |||||||
| Slamon et al, 2011 | 2,149 | 1,073 | Concurrent | (q3w) (Dox+Cyc+Doc)+(w→q3w) T | (q3w) (Dox+Cyc+Doc) (q3w) Doc+Car+(w→q3w) T | 65.0 | (31) |
| Perez et al, 2011 | 2,028 | 2,017 | Concurrent | (q3w) (Dox+Cyc)+wP+ wT | (q3w) (Dox+Cyc)+wP | 46.8 | (32) |
| Gianni et al, 2011 | 3,397 | 1,698 | Sequential | (q3w) T for 1 year | Observation (q3w) T for 2 years | 48.4 | (33) |
| von Minckwitz et al, 2009 | 78 | 78 | Concurrent | Cap+(q3w) T | Cap | 15.6 | (34) |
| Spielman et al, 2009 | 260 | 268 | Sequential | (q3w)T+(F+E+Cyc)/(E+Doc) | (F+E+Cyc)/(E+Doc) | 47.0 | (35) |
| Joensuu et al, 2009 | 116 | 116 | Concurrent | Doc+F+E+Cyc+T V+F+E+Cyc+T | Doc+F+E+Cyc V+F+E+Cyc | 62.0 | (36) |
| Gasparini et al, 2007 | 63 | 60 | Sequential | wP+wT | wP | 16.6 | (37) |
| Marty et al, 2005 | 92 | 94 | Concurrent | (q3w) Doc+wT | (q3w) Doc | 40.9/35.9b | (38) |
| Slamon et al, 2001 | 235 | 234 | Concurrent (q3w) P+T | (q3w) (A+Cyc)+wT (q3w) P | (q3w) (A+Cyc) | 35.0 | (39) |
| Neoadjuvant chemotherapy | |||||||
| Steger et al, 2014 | 44 | 49 | Concurrent | (q3w) (E+Doc±Cap)+T | (q3w) (E+Doc±Cap) | NR | (40) |
| Pierga et al, 2010 | 62 | 58 | Concurrent | (q3w) (E+Cyc+Doc)+(q3w) T | (q3w) (E+Cyc+Doc) | NR | (41) |
| Gianni et al, 2010 | 117 | 118 | Concurrent (Cyc+M+F)+(q3w) T | (q3w) (Dox+P)+(q4w) | (q3w) (Dox+P)+(q4w) (Cyc+M+F) | 38.4 | (42) |
| Buzdar et al, 2007 | 23 | 19 | Concurrent | P+F+E+Cyc+wT | P+F+E+Cyc | 36.1 | (43) |
a
Median value
b
follow-up for T-group and C-group are 40.9 and 35.9 months. T-group, trastuzumab plus chemotherapy group; C-group, chemotherapy alone group; A, anthracycline; Cap, capecitabine; Cyc, cyclophosphamide; Car, carboplatin; Dox, doxorubicin; Doc, docetaxel; E, epirubicin; F, fluorouracil; M, methotrexate; P, paclitaxel; V, vinorelbine; T, trastuzumab; w, weekly; q3w, every 3-weeks; NR, no report.